| __timestamp | BioCryst Pharmaceuticals, Inc. | Exelixis, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 51796000 | 189101000 |
| Thursday, January 1, 2015 | 72758000 | 96351000 |
| Friday, January 1, 2016 | 61008000 | 95967000 |
| Sunday, January 1, 2017 | 66962000 | 112171000 |
| Monday, January 1, 2018 | 84888000 | 182257000 |
| Tuesday, January 1, 2019 | 107068000 | 336964000 |
| Wednesday, January 1, 2020 | 122964000 | 547851000 |
| Friday, January 1, 2021 | 208808000 | 693716000 |
| Saturday, January 1, 2022 | 253297000 | 891813000 |
| Sunday, January 1, 2023 | 216566000 | 1044071000 |
| Monday, January 1, 2024 | 910408000 |
Infusing magic into the data realm
In the competitive world of biotechnology, innovation is the lifeblood of success. Over the past decade, Exelixis, Inc. and BioCryst Pharmaceuticals, Inc. have been at the forefront of this race, each investing heavily in research and development (R&D) to drive breakthroughs. From 2014 to 2023, Exelixis consistently outpaced BioCryst in R&D spending, with a staggering 400% increase, peaking at over $1 billion in 2023. In contrast, BioCryst's investment grew by approximately 320%, reaching its highest at $253 million in 2022. This significant difference highlights Exelixis's aggressive strategy to lead in innovation. The data underscores the importance of R&D in maintaining a competitive edge in the biotech industry, where the stakes are high, and the rewards are transformative. As these companies continue to push the boundaries of science, their financial commitment to innovation remains a critical factor in their ongoing success.
Research and Development Expenses Breakdown: Novo Nordisk A/S vs Exelixis, Inc.
Who Prioritizes Innovation? R&D Spending Compared for GSK plc and Exelixis, Inc.
Research and Development Investment: argenx SE vs BioCryst Pharmaceuticals, Inc.
Research and Development Investment: Insmed Incorporated vs Exelixis, Inc.
R&D Insights: How Sarepta Therapeutics, Inc. and Exelixis, Inc. Allocate Funds
Exelixis, Inc. vs Protagonist Therapeutics, Inc.: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for Exelixis, Inc. and Arrowhead Pharmaceuticals, Inc.
R&D Spending Showdown: Exelixis, Inc. vs Wave Life Sciences Ltd.
R&D Insights: How Exelixis, Inc. and Celldex Therapeutics, Inc. Allocate Funds
R&D Spending Showdown: Exelixis, Inc. vs Taro Pharmaceutical Industries Ltd.
Research and Development Investment: Corcept Therapeutics Incorporated vs BioCryst Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: CRISPR Therapeutics AG vs BioCryst Pharmaceuticals, Inc.